Asset Details
Do you wish to reserve the book?
MET inhibitors for targeted therapy of EGFR TKI-resistant lung cancer
Hey, we have placed the reservation for you!
By the way, why not check out events that you can attend while you pick your title.
Oops! Something went wrong.
Looks like we were not able to place the reservation. Kindly try again later.
Are you sure you want to remove the book from the shelf?
MET inhibitors for targeted therapy of EGFR TKI-resistant lung cancer
Do you wish to request the book?
MET inhibitors for targeted therapy of EGFR TKI-resistant lung cancer
Please be aware that the book you have requested cannot be checked out. If you would like to checkout this book, you can reserve another copy
We have requested the book for you!
Your request is successful and it will be processed during the Library working hours. Please check the status of your request in My Requests.
Oops! Something went wrong.
Looks like we were not able to place your request. Kindly try again later.
Journal Article
MET inhibitors for targeted therapy of EGFR TKI-resistant lung cancer
2019
Overview
Treatment of non-small cell lung cancer (NSCLC) harboring epidermal growth factor receptor (EGFR) activating mutation with EGFR-TKIs has achieved great success, yet faces the development of acquired resistance as the major obstacle to long-term disease remission in the clinic.
MET
(or
c-MET
) gene amplification has long been known as an important resistance mechanism to first- or second-generation EGFR-TKIs in addition to the appearance of T790 M mutation. Recent preclinical and clinical studies have suggested that
MET
amplification and/or protein hyperactivation is likely to be a key mechanism underlying acquired resistance to third-generation EGFR-TKIs such as osimertinib as well, particularly when used as a first-line therapy. EGFR-mutant NSCLCs that have relapsed from first-generation EGFR-TKI treatment and have
MET
amplification and/or protein hyperactivation should be insensitive to osimertinib monotherapy. Therefore, combinatorial therapy with osimertinib and a MET or even a MEK inhibitor should be considered for these patients with resistant NSCLC carrying
MET
amplification and/or protein hyperactivation.
Publisher
BioMed Central,BioMed Central Ltd,Springer Nature B.V,BMC
Subject
/ Acrylamides - therapeutic use
/ Aniline Compounds - pharmacology
/ Aniline Compounds - therapeutic use
/ Animals
/ Antineoplastic Agents - pharmacology
/ Antineoplastic Agents - therapeutic use
/ Carcinoma, Non-Small-Cell Lung - drug therapy
/ Carcinoma, Non-Small-Cell Lung - genetics
/ Emerging agents and regimens for cancer therapy
/ Epidermal growth factor receptors
/ ErbB Receptors - antagonists & inhibitors
/ Genes
/ Humans
/ Kinases
/ Ligands
/ Lung Neoplasms - drug therapy
/ Medicine
/ Mutation
/ Non-small cell lung carcinoma
/ Oncology
/ Protein Kinase Inhibitors - pharmacology
/ Protein Kinase Inhibitors - therapeutic use
/ Proteins
/ Proto-Oncogene Proteins c-met - antagonists & inhibitors
/ Proto-Oncogene Proteins c-met - genetics
/ Review
